• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Structural insights into proprotein convertase activation facilitate the engineering of highly specific furin inhibitors

tetano

Editor, Senior Moderator
Nat Commun


. 2025 Sep 2;16(1):8206.
doi: 10.1038/s41467-025-63479-y. Structural insights into proprotein convertase activation facilitate the engineering of highly specific furin inhibitors

Rupert Klaushofer[SUP] #[/SUP][SUP] 1 2 [/SUP], Konstantin Bloch[SUP] #[/SUP][SUP] 3 [/SUP], Luisa Susanna Eder[SUP] 1 2 [/SUP], Simone Marzaro[SUP] 1 [/SUP], Mario Schubert[SUP] 1 [/SUP], Eva Böttcher-Friebertshäuser[SUP] 3 [/SUP], Hans Brandstetter[SUP] 1 2 [/SUP], Sven O Dahms[SUP] 4 5 [/SUP]



Affiliations
Abstract

Proprotein convertases (PCs), including furin and PC1/3 among nine mammalian homologues, mediate the maturation of numerous secreted substrates by proteolytic cleavage. Disbalance of PC activity is associated with diseases like cancer, fibrosis, neurodegeneration and infections. Therefore, PCs are promising drug targets for the treatment of many diseases. However, the highly conserved active site of PCs complicates the development of specific inhibitors. Here we investigate the activation mechanism of PCs using X-ray crystallography and biochemical methods. The structure-based optimization of the multibasic secondary cleavage site loop not only prevents the prodomain's proteolytic cleavage but also increases its inhibition of furin. Combination of cleavage-resistant PC1/3-prodomain variants and a furin-specific nanobody in fusion proteins reveal very potent inhibitors (K[SUB]i[/SUB] = 1.2 pM) with a more than 25,000-fold higher specificity for furin compared to the closely related PC-member PCSK5. Such fusion proteins effectively suppress the replication of a furin-dependent H7N7-influenza virus in cell-based assays.


 
Back
Top